EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients

Natthakul Akarapredee, Chalirmporn Atasilp, Chonlaphat Sukasem, Pimonpan Jinda, Rattanaporn Sukprasong, Jiraporn Jensuriyarkun, Soravit Wongjitjanyong, Patompong Satapornpong, Natchaya Vanwong iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0338442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Natthakul Akarapredee und 8 weiteren Autor:innen. Beteiligte Einrichtung: The M.Sc. Program in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn…. Hauptthemen laut MEDLINE: Irinotecan, Colorectal Neoplasms, Polymorphism, Single Nucleotide, Glucuronosyltransferase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Chulalongkorn University Graduate Scholarship to Commemorate the 72nd Anniversary of His Majesty King Bhumibol Adulyadej, the 90th Anniversary of Chulalongkorn University Fund, the Thailand Science Research and Innovation Fund, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Irinotecan is a chemotherapy agent commonly prescribed for metastatic colorectal cancer but often leads to neutropenia. Variations in genes encoding drug-metabolizing enzymes and transporters may affect the toxicity and effectiveness of irinotecan. This study aimed to examine the impact of these genetic polymorphisms on irinotecan outcomes in Thai colorectal cancer patients.

Methods

The study retrospectively analyzed 41 metastatic colorectal cancer patients treated with irinotecan-based chemotherapy. Genotyping was conducted for 23 single nucleotide polymorphisms in genes including UGT1A1, CYP3A4, CYP3A5, CES1, ABCB1, ABCC2, ABCC5, ABCG1, ABCG2, and SLCO1B1 .Toxicity and efficacy were assessed, with statistical significance set at a Bonferroni-corrected P value < 0.002.

Results

In terms of toxicity, UGT1A1*6 was significantly associated with both all-grade and severe neutropenia in the first cycle ( p < 0.001) and severe neutropenia in the second cycle ( p < 0.002). Lower absolute neutrophil count was observed among intermediate and poor UGT1A1 metabolizers ( p < 0.001). The ABCC2 -24C > T variant was linked to all-grade neutropenia in the second cycle ( p = 0.001). For efficacy, patients with the wild-type UGT1A1* 6 had longer progression-free survival (PFS) ( p < 0.002). Additionally, the SLCO1B1 521T > C variant was associated with improved PFS ( p < 0.002).

Conclusion

UGT1A1*6 and ABCC2 -24C > T variants emerge as potential predictors of irinotecan-induced neutropenia, while UGT1A1*6 and SLCO1B1 521T > C may serve as markers of prolonged PFS in Thai patients. Validation through larger prospective studies is essential to confirm and refine these genetic associations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IrinotecanColorectal NeoplasmsPolymorphism, Single NucleotideGlucuronosyltransferaseHumansMaleFemaleMiddle AgedMultidrug Resistance-Associated Protein 2AgedThailandAdultRetrospective StudiesNeutropeniaGenotypeATP-Binding Cassette, Sub-Family C ProteinsSoutheast Asian PeopleUGT1A1 Enzyme

Substanzen

IrinotecanMultidrug Resistance-Associated Protein 2GlucuronosyltransferaseATP-Binding Cassette, Sub-Family C ProteinsUGT1A1 EnzymeABCC2 protein, human

Autor:innen und Institutionen

  • The M.Sc. Program in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.
  • Department of Pathology, Division of Pharmacogenomics and Personalized Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Laboratory for Pharmacogenomics, Clinical Pathology, Ramathibodi Hospital, Bangkok, Thailand.
  • Division of General Pharmacy Practice, Department of Pharmaceutical Care, College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
  • Excellence Pharmacogenomics and Precision Medicine Centre, College of Pharmacy, Rangsit University, Pathum Thani, Thailand.

ORCID-Profile: Natchaya Vanwong

Förderung

  • the Chulalongkorn University Graduate Scholarship to Commemorate the 72nd Anniversary of His Majesty King Bhumibol Adulyadej
  • the 90th Anniversary of Chulalongkorn University Fund
  • the Thailand Science Research and Innovation Fund, Chulalongkorn University
  • Benoziyo Endowment Fund for the Advancement of Science

Zitieren

APA

Akarapredee, N., Atasilp, C., Sukasem, C., Jinda, P., Sukprasong, R., Jensuriyarkun, J., Wongjitjanyong, S., Satapornpong, P., & Vanwong, N. (2025). Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients. PLOS One. https://doi.org/10.1371/journal.pone.0338442

Vancouver

Akarapredee N, Atasilp C, Sukasem C, Jinda P, Sukprasong R, Jensuriyarkun J, et al. Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients. PLOS One. 2025. doi:10.1371/journal.pone.0338442

BibTeX
@article{Akarapredee2025,
  author = {Akarapredee, Natthakul and Atasilp, Chalirmporn and Sukasem, Chonlaphat and Jinda, Pimonpan and Sukprasong, Rattanaporn and Jensuriyarkun, Jiraporn and Wongjitjanyong, Soravit and Satapornpong, Patompong and Vanwong, Natchaya},
  title = {Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0338442}
}
Kostenlos starten →